Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Deimmunization of monoclonal antibodiesTim D Jones, Laura J Crompton, Frank J Carr, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 9, 2010
Prediction of immunogenicity of therapeutic proteins: validity of computational toolsChristine J Bryson, Tim D Jones, Matthew P BakerJournal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|September 29, 2004
The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infectionTim D Jones, Marian Hanlon, Beverley J Smith, et al.Mabs|January 30, 2016
A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donorsCarl I Webster, Christine J Bryson, Edward A Cloake, et al.Protein Engineering, Design & Selection : PEDS|September 1, 2016
A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warheadTim D Jones, Arron R Hearn, Robert G E Holgate, et al.Critical Reviews in Microbiology|January 28, 2003
The lactic acid bacteria: a literature surveyFrank J Carr, Don Chill, Nino MaidaCurrent Drug Safety|July 10, 2010
Pre-clinical considerations in the assessment of immunogenicity for protein therapeuticsMatthew P Baker, Francis J CarrCurrent Opinion in Drug Discovery & Development|April 18, 2007
Identification and removal of immunogenicity in therapeutic proteinsMatthew P Baker, Timothy D JonesIdrugs : the Investigational Drugs Journal|April 8, 2009
Circumventing immunogenicity in the development of therapeutic antibodiesRobert G E Holgate, Matthew P BakerPageof 3